Steroid‐free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation: Long‐term longitudinal follow‐up

• Published in: Pediatric transplantation Vol. 26; no. 2; pp. e14173 - n/a
• Main Authors: Jain, Ashokkumar, Daoud, Deborah, Kees‐Folts, Deborah, Freeman, Michael A., Butt, Fauzia, Abendroth, Catherine S., Shike, Hiroko, Kadry, Zakiyah
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.03.2022
• Subjects: Adolescent; Alemtuzumab - therapeutic use; Antihypertensives; Blood pressure; Body mass index; Child; Child, Preschool; CMV; Corticosteroids; Cytomegalovirus; Cytomegalovirus Infections - etiology; EBV; Epstein-Barr virus; Epstein-Barr Virus Infections - etiology; Female; Graft Rejection; Humans; Immunosuppression; Immunosuppression Therapy - methods; Immunosuppressive Agents - administration & dosage; Infant; infection; Kidney Transplantation; Kidney transplants; Lymphocytes; Lymphoproliferative Disorders - etiology; Male; Monoclonal antibodies; Mycophenolic Acid - administration & dosage; Neutropenia; Patients; Pediatrics; Posttransplant lymphoproliferative disorders; PTLD; rejection; Steroids; Tacrolimus - administration & dosage; Viremia; EBV; BK; PTLD; infection; CMV; rejection
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14173

Background There is a scarcity of long‐term data on steroid‐free immunosuppression using alemtuzumab in pediatric kidney transplantation (KTx). This study examines long‐term outcomes with alemtuzumab without steroid maintenance therapy in pediatric KTx. Methods From July 2005 to June 2015, 71 pediatric KTx recipients received alemtuzumab without steroid maintenance. They were followed from 4.1 to 14.1 years post KTx. Results Patient survival: One child expired with a functioning graft from post‐transplant lymphoproliferative disorder (PTLD). Patient survival was 98.6%. Graft survival: Eighteen grafts were lost (16 from chronic rejection). Graft survival at 5 and 10 years was 92.3% and 61.3%, respectively. Rejection: Twenty‐three (32.4%) patients were free from T‐cell‐mediated rejection (TCMR), 16 (22.5%) had >3 episodes. Sixteen (22.5%) were treated for antibody‐mediated rejection (AMR). Infection: Twenty‐three children developed Epstein‐Barr virus (EBV), 5 developed cytomegalovirus (CMV), and 20 developed BK virus infection. Four (5.6%) developed PTLD. Twenty‐two (31.0%) required treatment for neutropenia. Growth parameters: Mean height and weight increased by 0.56 and 0.69 SDS (standard deviation score), respectively. Body mass index increased by 5.1 kg/m2 at 10 years. Less than 40% required antihypertensive medications at all‐time points. Conclusion Alemtuzumab, without corticosteroid maintenance, offers 98.6% patient survival at 14 years with five and 10‐year graft survival of 92.3% and 61.3%, respectively. TCMR and AMR requiring treatment were 67.4% and 22.5%, respectively. CMV, EBV, and BK viremia rates were 7.0%, 32.4%, and 28.2%, respectively. Thirty‐one percent were treated for neutropenia; 5.6% developed PTLD. There were improvements in growth parameters and blood pressure.